IN THE SPOTLIGHT

Using T cells to Tackle Drug Resistance in EGFR+ Lung Cancer

Using T cells to Tackle Drug Resistance in EGFR+ Lung Cancer

Approximately 10%-15% of patients with non-small cell lung cancer have tumors with mutations in the EGFR (epidermal growth factor receptor) gene. EGFR mutations are known to drive cancer growth. Many patients living with EGFR-positive lung cancer benefit from targeted therapies called tyrosine kinase inhibitors (TKIs). TKIs, such as osimertinib, can help patients by specifically blocking the effect of these mutations and reducing tumor growth. However, TKI-treated tumors eventually develop drug…

Drs. Susumu Kobayashi and Alexandre Reuben Announced as Recipients of EGFR Resisters/LUNGevity Research Award

Drs. Susumu Kobayashi and Alexandre Reuben Announced as Recipients of EGFR Resisters/LUNGevity Research Award

LUNGevity Foundation is thrilled to announce the recipients of the EGFR Resisters/LUNGevity Research Award for EGFR-Positive Lung Cancer.EGFR Resisters, a vibrant patient-led community advocating for improved treatment options for patients with EGFR-positive lung cancer, has partnered with LUNGevity for the second time to support high-impact research focused on EGFR-positive lung cancer.“We are pleased to partner with LUNGevity again on patient-directed research to address the unmet needs of…

LUNGevity Announces $1.2M in Lung Cancer Workforce Development Research Awards

LUNGevity Announces $1.2M in Lung Cancer Workforce Development Research Awards

LUNGevity Foundation is proud to announce the recipients of four awards to bolster the lung cancer research workforce— the Career Development Award, the VA Research Scholar Award, the Health Equity and Inclusiveness Research Fellow Award, and the ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant.“Progress in lung cancer research is only possible with a vibrant and diverse thoracic oncology workforce,” notes Upal Basu Roy, PhD, MPH, executive director, LUNGevity Research. “We…

Treatment & Research Takeaways: ESMO 2023 Meeting

Treatment & Research Takeaways: ESMO 2023 Meeting

The European Society for Medical Oncology (ESMO) recently held its annual conference from October 20 – 24, 2023 in Madrid, Spain. ESMO represents one of the largest gatherings of the international oncology community, and this year’s meeting had over 30,000 registered attendees from around the world.  Though October 19th brought record rainfall to Madrid, breaking a 100-year record, the rain in Spain didn’t dampen the palpable excitement of this year’s meeting. This was an especially…

What Is a Clinical Trial

What Is a Clinical Trial

Lung cancer clinical trials are carefully designed research studies to evaluate and learn more about new drugs and treatments. They give people the ability to participate in lung cancer research and access to new treatments that otherwise may not be available to them, all under the close supervision of medical experts. 

Watch Recorded Expert Sessions From ILCSC

Watch Recorded Expert Sessions From ILCSC

The International Lung Cancer Survivorship Conference (ILCSC) is a free virtual educational conference for people with lung cancer, caregivers, and advocates. The 2023 conference was held September 22-23.  The recorded sessions from this conference are available to registered participants through December 21, 2023, at www.lungevity.org/ilcsc. If you did not register for the conference but would like to view the recordings, you may still register for free access. The recordings are…

The Latest Lung Cancer Science: Highlights of WCLC 2023

The Latest Lung Cancer Science: Highlights of WCLC 2023

I had the privilege of attending the 2023 World Conference on Lung Cancer (WCLC) in Singapore with my colleague Dr. Bellinda King-Kallimanis. WCLC, the world's largest meeting dedicated to lung cancer and other thoracic malignancies, is an excellent forum for learning about the latest research into the early detection and treatment of lung cancer. Apart from the science, it was inspiring to see fellow advocates and network with brilliant researchers, all razor-focused on improving the outcomes…

Decentralized Trials: Bringing Clinical Trials Closer to the Patient

Decentralized Trials: Bringing Clinical Trials Closer to the Patient

While participating in clinical trials can provide substantial benefits to people with lung cancer, the resources required to do so may pose significant hurdles, especially to those who don’t live close to where trials are held, such as academic medical centers or major oncology network sites. Decentralized clinical trials remove some hurdles to trial participation for patients and are thus important for improving trial access for larger and more diverse groups of people. The U.S. Food and Drug…

2023 ASCO: Highlights of Lung Cancer Research

2023 ASCO: Highlights of Lung Cancer Research

Recently, members of LUNGevity Foundation joined thousands of attendees from the US and around the world, including oncologists, scientists, biotech and pharmaceutical representatives, advocates, and patients, to discuss lifesaving cancer research at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 2 through June 6, 2023. The theme for this year’s conference, “Partnering With Patients: The Cornerstone of Cancer Care and Research,” was in recognition of…

Tracing the Clues of a Global Killer: How Dr. Charles Swanton’s Research Is Shedding New Light on Lung Cancer

Tracing the Clues of a Global Killer: How Dr. Charles Swanton’s Research Is Shedding New Light on Lung Cancer

As Chief Investigator of the groundbreaking Cancer Research UK (CRUK) TRACERx study, you could say that Dr. Charles Swanton is having a moment. Launched nine years ago, TRACERx seeks to understand lung cancer at its most basic level, “tracing” the clues that may predict how it starts and eventually changes over time so that doctors can treat it better.Collecting comprehensive genomic and clinical data from over 800 people with non-small cell lung cancer (NSCLC), Dr. Swanton and a team of…

EGFR+ Lung Cancer: Going Beyond Osimertinib

EGFR+ Lung Cancer: Going Beyond Osimertinib

Learn about what's next once osimertinib stops working in EGFR+ lung cancer. EGFR Resisters co-founders Jill Feldman and Ivy Elkins, and 2021 EGFR Resisters/LUNGevity Foundation awardees Christine Lovly, MD, PhD, and Helena Yu, MD, share updates for the community. This video was recorded on Facebook Live on May 11, 2023.

Tackling the Biggest Challenges in Cancer

Tackling the Biggest Challenges in Cancer

Cancer Grand Challenges is a partnership between Cancer Research UK (CRUK) and the National Cancer Institute (NCI), which funds global teams of leading researchers across various scientific disciplines to tackle some of the toughest challenges in cancer research. As Dinah Singer, Acting Director of NCI’s Center for Strategic Scientific Initiatives says, “Cancer research is a global endeavor.” As LUNGevity’s Vice President of Global Engagement and Patient Partnerships, I recently attended…

RET, MET, and EGFR: An unusual tale of three oncogenes in lung cancer

RET, MET, and EGFR: An unusual tale of three oncogenes in lung cancer

LUNGevity's Upal Basu Roy, PhD, MPH, Executive Director, Research,  discusses innovative research into RET+ NSCLC with patient advocates and the scientist conducting the studies.  Panelists include Omaima Salous (diagnosed with RET+ NSCLC and co-founder of The Hamoui Foundation), Dr. Hilary Hammell (diagnosed with RET+ NSCLC and co-chair of RETpositive), and Dr. Tejas Patil (Assistant Professor, University of Colorado). The discussion focuses on Dr. Patil’s RET+ NSCLC research project…

Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting

Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting

The development of new treatments for any disease relies on the collaborative efforts of many different stakeholders, such as scientists, clinicians, patient advocacy groups, regulators, and pharmaceutical and biotech companies. During scientific conferences that happen throughout the year, stakeholders cobble together opportunities to discuss the current state of treatments and strategize ways to bring emerging lifesaving treatments to patients. Each year, there is one key conference…

Researchers Make New Inroads for EGFR Exon20+ NSCLC Patients

Researchers Make New Inroads for EGFR Exon20+ NSCLC Patients

While our bodies can have a wide range of naturally occurring, harmless mutations in different genes, some mutations, called driver mutations, are key to driving the development of cancer. There are many driver mutations. Researchers have been developing drugs that target specific driver mutations in lung cancer, creating therapies for those patients whose lung cancer harbors them. Early Targeting of EGFR In the early 2000s, EGFR was the first gene in non-small cell lung cancer (NSCLC) to be…

Targeted Therapy Options for Patients with EGFR Exon20+ NSCLC

Targeted Therapy Options for Patients with EGFR Exon20+ NSCLC

Researchers have made tremendous progress in treating lung cancer by identifying key mutations in genes that drive the growth of lung cancer. Once these “driver” mutations are identified, researchers can work to target these mutations with specific treatments, called targeted therapies.FDA-approved targeted therapies exist for treating EGFR-positive NSCLC, or non-small cell lung cancer (NSCLC) patients whose tumors test positive for exon19 and exon21 L858R mutations in the EGFR (epidermal…

Science Spotlight: NSCLC Transformation into SCLC

Science Spotlight: NSCLC Transformation into SCLC

Take a behind-the-scenes look at how researchers study lung cancer. Join lung cancer researcher Triparna Sen, PhD, as she digs into what’s known about how EGFR-positive NSCLC cells transform into SCLC to escape targeted therapy treatment. SCLC transformation is a common resistance mechanism for multiple types of NSCLC, including EGFR, ALK, and RET. This Facebook Live event is hosted by Amy Moore, PhD, LUNGevity’s Vice President of Global Engagements and Patient Partnerships. Dr. Sen is Co-…

Key Findings from ASCO 2022

Key Findings from ASCO 2022

Upal Basu Roy, PhD, MPH, LUNGevity's Executive Director of Research, speaks with Charles Rudin, MD, PhD, about the key findings from the recent meeting of the American Society for Clinical Oncology (ASCO) and what they mean for the lung cancer community.

We're Live-Tweeting from ASCO June 3-7!

We're Live-Tweeting from ASCO June 3-7!

LUNGevity’s Dr. Upal Basu Roy and Dr. Amy Moore will be live-tweeting from the American Society of Clinical Oncology (ASCO) annual meeting. Follow LUNGevity on Twitter and the hashtags #ASCO22 and #LCSM to be a part of the action. Times and topics of live-tweeted sessions are as follows: Fri, Jun 3, 2022 | 2:00 PM – 5:00 PM EDT | Lung Cancer—Non-Small Cell Metastatic  Sun, Jun 5, 2022 | 9:00 AM – 10:15 AM EDT | Treatment Sequencing in Resectable Lung Cancer…

Lung Cancer Treatment Landscape: New Options and Ongoing Challenges

Lung Cancer Treatment Landscape: New Options and Ongoing Challenges

Drs. Upal Basu Roy, Amy Moore, and Dhru Deb discuss their recent publication in which they presented an analysis of the lung cancer drug pipeline. They talk about what it means for patients, new drugs under development for NSCLC and SCLC, and some of the ongoing challenges and opportunities this rapid growth means for the lung cancer community.

New Options in Adjuvant Therapy for Early-Stage NSCLC

New Options in Adjuvant Therapy for Early-Stage NSCLC

Historically, surgery has been the most effective treatment for patients with early-stage non-small cell lung cancer (NSCLC). While technological improvements, such as the development of minimally invasive techniques (such as video-assisted thoracoscopic surgery or VATS), have made surgeries safer for patients, the ability to cure early-stage NSCLC patients hasn’t improved significantly in recent decades. Even after successful surgeries that completely remove the visible tumor, about half of…

Studying Drug Resistance From a New Angle

Studying Drug Resistance From a New Angle

The development of “targeted therapies” which block the function of mutant proteins within tumor cells has revolutionized the treatment landscape for many cancers, most of all lung cancer. EGFR is one such protein which is often altered (mutated) in lung cancers. Over the past decade, multiple EGFR targeted therapies have been developed, with each generation of drugs becoming increasingly potent. At present, patients with advanced EGFR-mutated lung cancer are treated with osimertinib (Tagrisso…

Highlights of the 2022 AACR meeting

Highlights of the 2022 AACR meeting

The American Association for Cancer Research (AACR) 2022 meeting was held in New Orleans from April 9 to 13. Doctors and researchers worldwide joined together virtually and in person to make this year’s meeting one of the largest gatherings since the start of the pandemic. They shared the many exciting developments in cancer research and treatment that emerged over the last year. This year’s meeting is another testament to “Science doesn’t stop, and scientists never sleep!” Here, we discuss…